Experienced in Liver Embolization

Dr. Jairam Krishnamurthy

Oncology | Hematology
University Of Utah Adult Services
50 N Medical Dr, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Liver Embolization
University Of Utah Adult Services
50 N Medical Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jairam Krishnamurthy is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Krishnamurthy is rated as an Experienced provider by MediFind in Liver Embolization. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Liver Embolization. Dr. Krishnamurthy is currently accepting new patients.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NE
Hospital Affiliations
University Of Utah Hospital And Clinics
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 15 Less Insurance Carriers -

Locations

UNIVERSITY OF UTAH ADULT SERVICES
50 N Medical Dr, Salt Lake City, UT 84132
Other Locations
UNMC PHYSICIANS
Emile 42nd St, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy for Post and Pre-menopausal Patients With Early Stage Hormone Receptor Positive and Her-2/Neu Negative Breast Cancer
A Phase II Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy for Post and Pre-menopausal Patients With Early Stage Hormone Receptor Positive and Her-2/Neu Negative Breast Cancer
Enrollment Status: Recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drug: Palbociclib
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Procedure
Study Drugs: Palbociclib, Letrozole, Fulvestrant, Goserelin
Study Phase: Phase 2
View 6 Less Clinical Trials

35 Total Publications

Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain.
Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: July 10, 2025
Similar Doctors
Experienced in Liver Embolization
Dr. Glynn W. Gilcrease
Oncology | Hematology
Experienced in Liver Embolization
Dr. Glynn W. Gilcrease
Oncology | Hematology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-581-8793
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Glynn Gilcrease is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Gilcrease is rated as a Distinguished provider by MediFind in Liver Embolization. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Liver Embolization, and Endoscopy. Dr. Gilcrease is currently accepting new patients.

Experienced in Liver Embolization
Dr. Mark A. Lewis
Hematology Oncology | Oncology | Hematology
Experienced in Liver Embolization
Dr. Mark A. Lewis
Hematology Oncology | Oncology | Hematology

Ihc Health Services Inc

5121 S Cottonwood St, 
Murray, UT 
 (8.3 miles away)
801-507-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Lewis is a Hematologist Oncology specialist and an Oncologist in Murray, Utah. Dr. Lewis is rated as a Distinguished provider by MediFind in Liver Embolization. His top areas of expertise are Neuroendocrine Tumor, Familial Colorectal Cancer, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia, and Liver Embolization. Dr. Lewis is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krishnamurthy's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile